100390-76-9

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 9071392 is used as a chemical building block for the synthesis of various pharmaceutical compounds due to its structural features and reactive groups. Its role in this industry is crucial for creating new drugs and biologically active molecules that can address a range of health conditions and diseases.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry research, CHEMBRDG-BB 9071392 serves as a valuable component in the development and modification of drug candidates. Its unique structure allows researchers to explore its potential interactions with biological targets, which can lead to the discovery of novel therapeutic agents.
While the specific applications of CHEMBRDG-BB 9071392 are not extensively documented, its use as a building block in the pharmaceutical industry and medicinal chemistry research highlights its importance in the development of new and effective treatments. Further research and exploration of its properties may unlock additional applications and uses in various fields.

InChI:InChI=1/C12H15NO3/c1-2-3-4-11(14)13-10-7-5-9(6-8-10)12(15)16/h5-8H,2-4H2,1H3,(H,13,14)(H,15,16)

Upstream product

• 619-45-4 4-methoxycarbonyl aniline 
• 127007-34-5 methyl 4-(valerylamino)benzoate 
• 638-29-9 n-valeryl chloride 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 170804-63-4 2-(3,4-diaminophenyl)-4H-1-benzopyran-4-one 
• 170804-53-2 3-Nitro-4-pentanoylamino-benzoic acid 

Relevant academic research and scientific papers

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3- aminomethylquinolines: Reducing human ether-a-go-go-related gene (hERG) associated liabilities

Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino} ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.

Synthesis and antiaggregator activity of some new derivatives of 4H-benzopyran-4-one

A series of 2--4H-1-benzopyran-4-one analogues 7a-7e was synthesized by the reaction with 3',4'-diaminoflavone and aliphatic carboxylic acids. 3',4'-Diaminoflavone 6 was prepared via the reduction of 2-(4-amino-3-nitrophenyl)-4H-1-benzopyran-4-one 5a.The compounds 7a-e and 14a-f were tested in vitro for their inhibitory activities against human platelet aggregation induced by collagen, ADP and A23187.The compound with a COOR group as a side chain, 2-(2-akyloxycarbonyl-2,3-dihydro-1,4-benzodioxin -6-yl)-4H-1-benzopyran-4-one 14a-f, haspotent activity, and so compound 13 was also prepared as an analogue of series 14 and tested for its antiaggregator activity. 4H-1-benzopyran-4-one/ benzodioxane/ benzimidazole/ human platelet/ aggregation